Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Monday, November 3, 2014

Biogen and the National MS Society weigh in on the first reported death of an MS patient taking Tecfidera who developed PML.

Patient Taking Tecfidera for MS Dies of Rare Brain Infection
October 30, 2014
Biogen Idec Inc., maker of the popular multiple sclerosis (MS) pill dimethyl fumarate (Tecfidera), announced the death of a patient taking the drug who succumbed to complications from a rare brain infection. Executives broke the news during a conference call with analysts last Wednesday.
The brain infection known as progressive multifocal leukoencephalopathy (PML) took the life of a European patient who had been on the popular pill for more than four years. The patient was taking part in a long-term safety study of Tecfidera.
"The patient was a participant in the ongoing ENDORSE extension study," confirmed Catherine Falcetti, associate director of public affairs for Biogen, in an interview with Healthline.
“This patient was treated with Tecfidera for 4.5 years as part of the ENDORSE study,” explained Falcetti. “They developed PML and recently died due to complications associated with aspiration pneumonia.”

 Keep CURRENT and up to date,
with MS Views and News - OPT-IN here

No comments: